Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrent Mycoplasma pneumoniae and Epstein-Barr virus infections

doi:10.12998/wjcc.v12.i23.5346

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 23

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (950)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

HTML

528

Figures (1-1)

100

Tables (1-5)

101

Sum=748

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

131

Sum=169

Aug 16, 2024 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Aug 16, 2024; 12(23): 5346-5353
Published online Aug 16, 2024. doi: 10.12998/wjcc.v12.i23.5346

Table 1 Comparison of general data among Mycoplasma pneumoniae group, coinfection group and control group

Group	n	Age	Male/female	CRP in mg/L	Fever in days
Coinfection	165	5.31 ± 2.09	79/86	35.36 ± 10.09^e^,^f	8.16 ± 2.15^f
MP	165	5.26 ± 2.06	89/76	25.26 ± 8.06^e	5.16 ± 1.06
Control	165	5.19 ± 2.45	83/82	15.30 ± 4.09	-
F/t/χ²	-	0.031	0.632	219.653	9.863
P value	-	0.965	0.075	< 0.001	< 0.001

^eP < 0.001 vs control group.

^fP < 0.001 vs Mycoplasma pneumoniae (MP) group. Coinfection: Epstein-Barr virus coinfection in MP pneumonia; Control: Healthy children; CRP: C-reactive protein.

Citation: Hao YP. Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrent Mycoplasma pneumoniae and Epstein-Barr virus infections. World J Clin Cases 2024; 12(23): 5346-5353
URL: https://www.wjgnet.com/2307-8960/full/v12/i23/5346.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i23.5346